Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations

DOI: 10.1128/AAC.02516-18

Article Information

DOI

PubMed

Published By

History

^aPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA
^bDepartment of Medicine, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA
^cDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA
^dDepartment of Chemical Engineering, University of Michigan, Ann Arbor, Michigan, USA
^eDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA

Address correspondence to Véronique Dartois, veronique.dartois{at}rutgers.edu.
↵* Present address: Elsje Pienaar, Purdue University, Weldon School of Biomedical Engineering, West Lafayette, Indiana, USA.
J.S. and L.B. contributed equally to the present article.
Citation Sarathy J, Blanc L, Alvarez-Cabrera N, O’Brien P, Dias-Freedman I, Mina M, Zimmerman M, Kaya F, Ho Liang H-P, Prideaux B, Dietzold J, Salgame P, Savic RM, Linderman J, Kirschner D, Pienaar E, Dartois V. 2019. Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations. Antimicrob Agents Chemother 63:e02516-18. https://doi.org/10.1128/AAC.02516-18.